8.36

2.45% -0.21

After Hours: 8.39 0.03 +0.36%

Capricor Therapeutics Inc (CAPR)

Overview News Price History Option Chain Financials Why CAPR Down? Discussions Forecast Stock Split

Capricor Therapeutics Inc stock is traded at $8.36, with a volume of 1.90M. It is down -2.45% in the last 24 hours and up +0.84% over the past month. Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Previous Close:

$8.57

Open:

$8.61

24h Volume:

1.90M

Relative Volume:

0.31

Market Cap:

$486.04M

Revenue:

$11.13M

Net Income/Loss:

$-114.59M

P/E Ratio:

-3.6144

EPS:

-2.313

Net Cash Flow:

$-113.96M

1W Performance:

-7.73%

1M Performance:

+0.84%

6M Performance:

-72.04%

1Y Performance:

+28.22%

1-Day Range:

$8.30

$8.67

1-Week Range:

$8.27

$9.48

52-Week Range:

$2.96

$40.37

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Name

Capricor Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(310) 358-3200

Address

10865 ROAD TO THE CURE, SAN DIEGO, CA

Employee

231

Twitter

@Capricor

Next Earnings Date

2026-11-09

Latest SEC Filings

CAPR's Discussions on Twitter

Compare CAPR vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CAPR Capricor Therapeutics Inc	8.36	486.04M	11.13M	-114.59M	-113.96M	-2.313
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-30-25	Initiated	Alliance Global Partners	Buy
Jun-26-25	Initiated	B. Riley Securities	Buy
May-20-25	Initiated	Roth Capital	Buy
Oct-21-24	Initiated	Piper Sandler	Overweight
May-17-24	Initiated	Oppenheimer	Outperform
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight
Oct-26-22	Initiated	Ladenburg Thalmann	Buy
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy
Sep-15-17	Reiterated	H.C. Wainwright	Buy
Feb-13-17	Resumed	Rodman & Renshaw	Buy
Jul-06-16	Resumed	H.C. Wainwright	Buy
Jun-15-16	Initiated	ROTH Capital	Buy

View All

Capricor Therapeutics Inc Stock (CAPR) Latest News

Sep 26, 2026

CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire

Sep 26, 2026

CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - GlobeNewswire Inc.

Sep 26, 2026

CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - financialcontent.com

Sep 26, 2026

(CAPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Sep 26, 2026

Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 28, 2026Contact Levi & Korsinsky - ACCESS Newswire

Sep 26, 2026

Sep 25, 2026

Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 - The Globe and Mail

Sep 25, 2026

Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 | FinancialContent - financialcontent.com

Sep 25, 2026

Securities Fraud Class Action Filed Against Capricor Therapeutics, Inc. (CAPR)Levi & Korsinsky Reminds Investors of September 28, 2026 - accessnewswire.com

Sep 25, 2026

Levi & Korsinsky Notifies Capricor Therapeutics, Inc. (CAPR) InvestorsLead Plaintiff Deadline on September 28, 2026 - accessnewswire.com

Sep 25, 2026

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Capricor Therapeutics, Inc. (CAPR) Investors of September 28, 2026 Deadline - ACCESS Newswire

Sep 25, 2026

CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Sep 25, 2026

CAPRICOR DEADLINE SEPTEMBER 28th: Bragar Eagel & Squire, - GlobeNewswire

Sep 25, 2026

CAPR Stock On Track For Worst Week Ever After Regulatory Setback For DMD Therapy - Stocktwits

Sep 25, 2026

Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi & Korsinsky Urges Investors to Act Before September 28, 2026 - ACCESS Newswire

Sep 25, 2026

Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 28, 2026Contact Levi & Korsinsky - ACCESS Newswire

Sep 25, 2026

Sep 24, 2026

Kaplan Fox Announces a Securities Class Action Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)Lead Plaintiff Deadline is September 28, 2026 - The Globe and Mail

Sep 24, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCAPR - PR Newswire

Sep 24, 2026

September 28, 2026 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky - accessnewswire.com

Sep 24, 2026

CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Sep 24, 2026

CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review

Sep 24, 2026

CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar

Sep 24, 2026

Capricor Therapeutics Shareholder Alert: ClaimsFiler - GlobeNewswire

Sep 24, 2026

Kaplan Fox Continues to Remind Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors of the Lead Plaintiff Deadline on September 28, 2026 - The Globe and Mail

Sep 24, 2026

SueWallSt Reminds Capricor Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 28, 2026CAPR - PR Newswire

Sep 24, 2026

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Sep 24, 2026

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire

Sep 24, 2026

Sep 23, 2026